Company intelligence / Profile preview

Nuriduri

Dublin, Ireland

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Nuritas uses a proprietary AI-driven peptide discovery platform to identify, validate, and commercialize novel bioactive peptides from natural sources. The company has launched several branded ingredients for consumer health markets with human clinical data supporting efficacy. Its internal biopharma pipeline includes preclinical programs targeting fibrosis/NASH and oncology indications such as KRAS G12D-mutant cancers. The company's approach enables rapid generation of new peptide candidates across multiple therapeutic areas.

Therapeutic areas: OncologyImmunologyOtherGastroenterologyNeurologyInfectious Diseases
Modalities: PeptidesSmall molecule (peptide-based small molecules)Biologic (peptide biologics)
Industry: Biotech

Partnerships

NestleMars Inc.Sumitomo CorporationPharmaviteBASF

Beyond the preview

Go deeper on Nuriduri.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuriduri.

Explore the full profile